KALA BIO
KALA
53 hedge funds and large institutions have $1.36M invested in KALA BIO in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 15 closing their positions.
4% less call options, than puts
Call options by funds: $22K | Put options by funds: $23K
1.94% less ownership
Funds ownership: 10.36% → 8.42% (-1.9%)
16% less funds holding
Funds holding: 63 → 53 (-10)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
40% less capital invested
Capital invested by funds: $2.27M → $1.36M (-$909K)
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$25.9K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.6K |
| 3 |
Man Group
London,
United Kingdom
|
+$14.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12.6K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$8.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$81.7K |
| 2 |
Goldman Sachs
New York
|
-$73.8K |
| 3 |
E
Ergoteles
New York
|
-$66K |
| 4 |
State Street
Boston,
Massachusetts
|
-$46.3K |
| 5 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$46K |
KALA Hedge Fund Activity: Q3 2022 in Review
53 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q3 2022, worth a combined $1.36M — down 40% from $2.27M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of KALA and 5 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $25.9K. The largest seller was Vanguard Group, cutting an estimated $81.7K.
- 53 institutional investors held KALA BIO (KALA) as of Q3 2022, down from 63 in Q2 2022.
- Funds reported $1.36M of KALA BIO stock for Q3 2022, down 40% quarter-over-quarter.
- 5 funds opened new KALA BIO positions in Q3 2022 and 15 closed out, a net change of -10 holders.
- The largest KALA BIO buyer in Q3 2022 was Renaissance Technologies, an estimated $25.9K added.
- The largest KALA BIO seller in Q3 2022 was Vanguard Group, an estimated $81.7K sold.
Based on aggregated 13F filings for Q3 2022.